Neuphoria Therapeutics Inc. (formerly Bionomics Limited)

Basis of preparation

FY2023–FY2026: US GAAP in USD. FY2023 and FY2024 are restated comparatives in the 10-K filings.

FY2021–FY2022: Australian IFRS in AUD (Form 20-F and ASX Appendix 4E). These are presented separately because they are not comparable.

Per-share data: Retroactively adjusted for the 2,160:1 Scheme consolidation for FY2024 onward. FY2023 per-share data as published (–US$0.02 per ordinary share) is not comparable and is shown as n/d.

FY2026: The full-year income statement detail had not been fully extracted at cut-off. Where FY2026 figures are derived, the derivation is stated.

Income statement

Sources and derivations:

• 10-K FY2025 press release (29 Sep 2025); StockTitan XBRL extracts; 10-K FY2026 tax note (FY2025 pre-tax loss of US$837,998).

• FY2024 EBITDA is derived from StockTitan's +97.3% YoY change, so it is approximate.

• FY2026 net loss is derived from the 10-K FY2026 MD&A statement that net loss rose by US$13.1M versus FY2025 (0.4 + 13.1 ≈ 13.5). It is approximate.

FY2026 quarterly detail (USD millions; 10-Q filings via StockTitan)

Data note: Q2 FY2026 net income (+US$1.9M) and EPS (–US$0.77) have opposite signs in the aggregator extract. Positive net income likely reflects non-operating fair-value gains on warrant and contingent-consideration liabilities and FX. This is flagged as unreconciled.

Restructuring costs disclosed in the 9M FY2026 10-Q:

• employee termination of about US$1.4M;

• other restructuring of about US$0.4M (including right-of-use asset impairment);

• partly offset by about US$0.6M of refundable contract-termination credits.

Margins

Revenue CAGR is n/m: revenue went from zero to US$15.6M in FY2025 and is non-recurring milestone income.

Balance sheet

Sources and notes:

• 10-K FY2025 and FY2026; StockTitan.

• FY2026 cash is derived as FY2025 cash plus restricted cash (US$14.29M) plus the FY2026 net increase of US$5.58M, giving about US$19.87M including restricted cash.

• Q3 FY2026 (31 Mar 2026) cash was US$19.4M and the accumulated deficit US$186.9M (10-Q).

• No borrowings are reported; the bank and equipment loans were repaid in Apr-2021.

• Total liabilities include contingent consideration (from legacy acquisitions), warrant liabilities and leases.

• Intangibles other than goodwill: n/d.

Cash flow

Source: 10-K FY2026 MD&A liquidity table for FY2025–FY2026; StockTitan for FY2023–FY2024. Capex is immaterial and not separately disclosed in the extracts reviewed.

FY2026 financing came from the at-the-market (ATM) program: 3,398,869 shares sold for about US$18.5M gross. FY2025 ATM sales were 349,801 shares for about US$2.1M (10-K FY2026).

Ratios

Sources: StockTitan, derived from 10-K data. Asset turnover is computed as 15.6/28.6. ROIC and the cash conversion cycle are n/m for a pre-revenue biotech with no debt and no inventory. Interest-bearing debt/equity is 0.

Legacy Bionomics

Sources: Form 20-F FY2022; ASX Appendix 4E FY2022.

The FY2022 revenue was a CTx license fee. The FY2021 loss was flattered by a A$4.3M fair-value gain on contingent consideration linked to the Carina deal.

A Bionomics half-year report quotes 30 Jun 2022 cash as A$35,564,857, while the 20-F and 4E show A$33,564,857. This looks like a transcription discrepancy; the audited figure of A$33.56M is used here.

Commentary on trends, inflections and drivers

FY2021–FY2023: scale-up of clinical spend.

• Net loss rose from A$8.7M (FY2021) to A$21.8M (FY2022) and US$21.4M (FY2023).

• Drivers were the PREVAIL (SAD) and ATTUNE (PTSD) trials, the Nasdaq listing cost base, and US management build-out.

• The Dec-2021 Nasdaq IPO and later ADS offerings funded this phase.

FY2024: discipline before the Phase 3 bet.

• R&D fell 28% to US$9.4M as PREVAIL and ATTUNE wound down.

• Net loss was US$15.5M.

• Financing inflows of US$15.1M (a PIPE with warrants plus ATM issuance) kept cash flat at US$12.6M.

FY2025: milestone-driven near-breakeven.

• The US$15.0M Merck milestone (Mar-2025) plus the Carina milestone turned an otherwise ~US$16M operating cost base into a US$1.1M operating loss and a US$0.4M net loss.

• Operating cash flow was roughly zero.

• This was a one-off inflection. The underlying burn was unchanged: R&D US$9.0M plus G&A US$7.8M.

FY2026: failure, restructuring, dilution.

• Q1 carried the AFFIRM-1 close-out costs (R&D US$3.8M; net loss US$9.9M).

• After the 20 Oct 2025 failure, R&D collapsed (Q2 US$0.7M), headcount went to one person and leases were terminated.

• Net loss was about US$13.5M.

• The company sold about US$18.5M of stock through the ATM, much of it after the readout and during the proxy contest. Shares outstanding rose about 2.7x, from 1,978,460 (30 Jun 2025) to 5,411,334 (17 Sep 2026).

• Lynx1 attacked this dilution publicly, and it underpins the closing-cash condition of the Scancell deal.

Liquidity statements. The 9M FY2026 10-Q said cash would fund operations beyond the fourth quarter of FY2027. Boardroom Alpha separately flagged a "going-concern flag" on that filing. This is a discrepancy, unresolved from primary text.

Management guidance

• No financial guidance.

• The company expects to:

  • close the Scancell transaction in late calendar 2026;

  • keep spending minimal;

  • satisfy the at-least-US$10.0M closing net cash test.

• The separate 2026 annual meeting is on 2 Nov 2026. A special meeting on the merger will follow once the F-4 is effective.

Consensus

Sell-side coverage is effectively dormant. Consensus EPS for Q4 FY2026 was −US$0.56 and Q1 FY2027 −US$0.42 (Benzinga). There are no revenue estimates.

Bull case

1. Cash floor plus free optionality. The market cap of about US$18.8M sits at or below FY2026 cash of about US$19.9M, so the CVR (Merck, KAT6, IP sales, R&D tax credit) is priced at roughly zero.

2. KAT6 is a live Phase 3 asset with a big-pharma sponsor. The May-2026 distribution of A$1.416M shows the mechanism pays.

3. Scancell equity exposure. NEUP holders receive about 14.5% of a financed (US$89M), Nasdaq-listed oncology company with a Fast Track Phase 3 melanoma asset.

Bear case

1. Execution risk. The financing (at least US$75.0M) or the cash test could fail. With no standalone plan and a 2027 core patent cliff, failure leaves a shrinking shell.

2. Weakening CVR value. MK-1167 failed. Merck controls MK-4334 with limited information rights. CVR payouts are uncertain and deferred.

3. Scancell price risk. The consideration floats with an AIM micro-cap share price. The 24 Jul 2026 drop to US$3.64 and the 3 Oct price of US$3.47 suggest the market discounts the exchange value.

Catalysts and monitorables (next 12 months)

Analyst verdict

Bionomics, now Neuphoria Therapeutics, has completed the full life cycle of a single-mechanism CNS biotech. Its science was credible: alpha7 allosteric modulation, a positive PTSD Phase 2b, and a Merck partnership that paid US$15M in 2025. But its chosen registrational bet, acute as-needed treatment of social anxiety disorder, failed twice: PREVAIL in 2022 and AFFIRM-1 in October 2025.

Management's response was decisive on costs: one employee, no leases, and no internal R&D. It was controversial on capital: roughly US$18.5M of ATM issuance that nearly tripled the share count during an activist contest. The board won that contest convincingly and ran a competitive process that produced the Scancell reverse merger.

For investors, NEUP is no longer a drug-development equity. It is a special situation with three components:

1. Cash backing of roughly US$19–20M before transaction costs.

2. A CVR on royalty and milestone tails that depend entirely on Merck and Pfizer.

3. Conversion into Scancell ADSs, giving roughly a 14.5% stake in a financed late-stage melanoma immunotherapy company.

The share price near cash suggests the market assigns little value to either the CVR or the Scancell equity premium. That reflects real risks: financing conditions, the closing-cash test, AIM share-price volatility and the long-dated nature of CVR payments.

Our assessment is that downside appears cushioned by cash and the signed agreement, while upside is asymmetric but slow and uncertain.

The key swing factors are:

• whether Scancell completes its at-least-US$75M financing;

• whether Neuphoria delivers at least US$10M of closing net cash;

• whether Pfizer's KAT6 Phase 3 advances.

Investors with an investment case built on BNC210 itself should regard it as closed. Scancell will not fund it, and the 2027 composition-of-matter expiry erodes its standalone licensing value.

Rating framework: event-driven; hold through closing for holders comfortable with Scancell exposure; not suitable as a fundamental CNS investment.

---

Principal sources consulted

SEC filings: - Neuphoria Form 10-K FY2026 (filed Sep-2026) and FY2025 (filed Sep-2025); 10-Q for the period ended 31 Mar 2026.

• 8-Ks dated Dec-2025, Jan-2026 and Jul-2026; DEF 14A (Sep-2026).

• Lynx1 Schedule 13D/A and DFAN14A (Dec-2025); Bionomics Form 20-F FY2022.

ASX: Bionomics Appendix 4E and Annual Report FY2022; Appendix 4C (Jun-2022).

Company releases (GlobeNewswire): 4 Sep 2025; 29 Sep 2025; 20 Oct 2025; 27 Oct 2025; 11 Nov 2025; 24 Nov 2025; 1 Dec 2025; 4 Dec 2025; 26 Jun 2026; 23 Jul 2026.

Media and market data: Fierce Biotech (Jul-2026 and Jun-2026), Alliance News/Morningstar (Jun-2026), Trinity Delta research on Scancell (23 Jul 2026), StockTitan, MarketScreener, Benzinga, Yahoo Finance, PitchBook, Boardroom Alpha, MarketBeat, Simply Wall St.